Investment Rating - The investment rating for the company is "Add" (maintained) [2] Core Views - The company has shown a steady development in its pig farming business, with a significant improvement in breeding costs and stable cash flow [8] - The company plans to acquire a 51% stake in Qiangdu Livestock, which focuses on pig farming and sales, adopting a "self-breeding and self-raising" model to enhance its farming scale [8] - The company is expected to achieve revenue of 169.6 billion, 178.6 billion, and 186.4 billion yuan from 2025 to 2027, with net profits of 6.19 billion, 9.39 billion, and 11.61 billion yuan respectively [8] Financial Performance - In the first half of 2025, the company achieved a revenue of 8.847 billion yuan, a year-on-year increase of 10.68%, and a net profit of 338 million yuan, up 22.27% year-on-year [8] - The average breeding costs for the first and second quarters of 2025 were 13.2 yuan/kg and 12.6 yuan/kg respectively, indicating significant cost improvements [8] - The company’s cash flow remains stable, with a net cash flow from operating activities of 1.619 billion yuan in the first half of 2025, a year-on-year increase of 109.4% [8] Revenue and Profit Forecast - The projected revenue and profit figures for the company are as follows: - 2025E: Revenue of 16,960 million yuan, net profit of 619 million yuan - 2026E: Revenue of 17,859 million yuan, net profit of 939 million yuan - 2027E: Revenue of 18,642 million yuan, net profit of 1,161 million yuan [6][9]
天康生物(002100):养殖成本持续改善,业务稳健发展